Healthcare: 16 A-Grades and a Broken Insurance Model

Healthcare is two sectors pretending to be one. On paper, it looks strong: 16 A-grades out of 25 companies, a 19.9% median FCF margin, and a 4.1x debt load that's manageable. Dig one layer deeper and the story splits. Pharmaceutical companies are cash machines. Health insurers are a collapsing business model.

The Pharma Cash Machine

Gilead leads the sector at 32.1% FCF margin with an improving trend. That's real money flowing through the business, not accounting sleight of hand. AbbVie sits at 29.1% but earned a B-grade instead of an A because the trend is declining. Bristol-Myers Squibb, Vertex, and Regeneron all hover around 26-27% margins. All A-grades. All declining trends.

That trend pattern matters. Seven companies are improving, three are stable, and 15 are declining. The sector is getting worse, not better. When three-quarters of your top performers are heading in the wrong direction, you have a sector coasting on past success.

The pharmaceutical group still prints cash better than almost anyone. Margins above 20% are extraordinary in any sector. The healthcare threshold for an A-grade is 15% FCF margin. These companies are clearing that bar by 10+ percentage points. Even with declining trends, they're so far ahead that balance sheet issues or consistency problems would have to be severe to knock them down.

Take Biogen at 19.9% margin. That's the sector median. Still an A-grade. Still declining. The entire top half of this sector is above the threshold for excellence. That's not normal.

The Insurance Crater

Then you hit the insurers. UnitedHealth Group generates $324 billion in revenue and manages a 5.2% FCF margin. That's an F-grade. Declining trend. Humana sits at 2.0%. Also an F. Also declining. CVS clocks in at 1.9% with an improving trend. Still an F. Elevance Health posts 1.6%, declining, F-grade.

These aren't small companies having a bad quarter. These are the largest health insurers in the country, and they're structurally unable to convert revenue into cash. The model doesn't work. When your FCF margin is 2%, you're one bad quarter away from negative cash flow. You have no cushion. You're running a volume business with razor-thin economics, and healthcare costs don't trend downward.

The sector debt ratio of 4.1x looks fine until you realize it's being dragged up by the insurers. Pharma companies with 25%+ margins can carry debt comfortably. Insurers at 2% margins with multi-billion dollar debt loads are a different risk profile entirely.

CVS shows up as improving, but improving from 1.9% doesn't inspire confidence. You're still burning cash relative to revenue. The trend direction matters less when the base level is that weak.

Moderna's Collapse

Moderna posts a -126.8% FCF margin. The company is burning cash faster than it generates revenue. Grade F, but marked as improving. That improvement is coming off a base so catastrophic that any movement looks like progress. This isn't a turnaround story. This is a company that rode a pandemic wave and has no sustainable business model on the other side.

The COVID vaccine gold rush created a temporary profit center. That's gone. What's left is a biotech with no product diversity and a cash burn rate that would sink most companies. The improving trend means the bleeding has slowed. It hasn't stopped.

What the Grades Don't Tell You

Sixteen A-grades in a 25-company sector sounds dominant. It is, if you're looking at pharma in isolation. The sector's health depends entirely on which side of the split you're invested in. Own Gilead, Vertex, or Regeneron, and you're holding companies that generate cash at rates most sectors would envy. Own UnitedHealth or Humana, and you're holding a structurally challenged business model with margins that don't support the risk.

The trend breakdown is the real warning. Fifteen declining companies out of 25 means the sector is losing momentum. Even the cash-rich pharma names are slipping. Patent cliffs, pricing pressure, and R&D costs are eating into margins. These companies are still excellent by sector standards. They're just getting slightly less excellent every quarter.

The stable group is small: Zoetis at 24.1%, DexCom at 23.1%, and Medtronic at 15.5%. Three companies out of 25 are holding steady. The rest are either improving from disaster levels or declining from strong positions.

The Sector's Real Problem

Healthcare should be a defensive sector. It's not optional spending. People need drugs, devices, and insurance regardless of economic conditions. The sector's performance suggests otherwise. When your median performer is declining and your bottom tier is structurally broken, the defensive thesis falls apart.

The pharma side still works. Margins are strong, balance sheets are manageable, and even declining trends leave most names well above the threshold for an A-grade. The insurance side is a catastrophe. Sub-5% margins with declining trends and multi-billion dollar revenue bases create systemic risk.

Healthcare gets lumped into one sector, but it's two businesses with opposite trajectories. One prints cash. The other burns it. The aggregate numbers hide that split. The individual company data makes it obvious.

If you're sector-shopping, healthcare looks strong on the surface. If you're stock-picking, you need to know which half of the sector you're in. The A-grades are real. So are the F-grades. Both exist in the same sector, and the gap between them is getting wider.